В

2001 6

| | , | | |
|--|---|---|--|
| | | , | |
| | | , | |
| | | | |
| | | • | |
| | | | |
| | | | |
| | | | |

| | 1 | |
|------|---|--|
| | 3 | |
| • | 5 | |
| 1. | 5 | |
| 2. | 5 | |
| 가. | 5 | |
| | 7 | |
| 3. | 7 | |
| 4. | 7 | |
| | 8 | |
| 1. | 8 | |
| 가. B | | |
| | 8 | |
| | 8 | |

| | | 9 |
|----|----|--|
| 2. | | 12 |
| 3. | В | |
| 4 | | 13 |
| 4. | | |
| | В | 14 |
| | 가. | ······································ |
| | | / |
| | | 15 |
| | | 16 |
| | | 17 |
| | | 18 |
| | | 23 |
| | | 25 |
| | | 28 |

| Figure 1. Age distribution | 9 |
|---|---|
| Figure 2. Lobular activity score according to | |
| histopathologic classification of | |
| nephropathy 1 | 4 |
| Figure 3. Porto - periportal activity score | |
| according to histopathologic | |
| classification of nephropathy 1 | 5 |
| Figure 4. Hepatitis activity index according to | |
| histopathologic classification of | |
| nephropathy 1 | 6 |
| Figure 5. Fibrosis score according to | |
| histopathologic classification of | |
| nephropathy1 | 7 |

| Table 1. | New histopathologic classification | |
|----------|--|----|
| | of chronic hepatitis | 6 |
| Table 2. | Laboratory findings in patients with | |
| | HBV - associated nephropathy at the | |
| | time of biopsy | 11 |
| Table 3. | Immunofluorescent findings in patients | |
| | with HBV - associated nephropathy | 12 |
| Table 4. | Histopathologic characteristics of | |
| | nephropathy according to new | |
| | histopathologic classification of | |
| | chronic hepatitis | 13 |

В

| | | В | | (HBV) | | 5 - 10% | % | HBV가 |
|----|----------|------|---------------|---------|------|---------|----------------|-------|
| 가 | HBV | | | · | | I | HBV가 | , HBV |
| | | | | | НВ | sAg | | |
| | | | | 가 | | | | |
| | HBsAg | | | | | Н | BV | |
| | | | , В В | | | , | | |
| | , HBV | | D | | | | | • |
| | | 1985 | 2000 | 6 | | | | |
| | | | HBsAg | | | | | 26 |
| 1. | | 26 | | 31.0 ± | 12.3 | | | 4.2:1 |
| 2. | · | 20 | 6 14 | | 가 | | | |
| 3. | В | 1 | 26 (3.8%), | IgA | g | | 7.0%), .6%) | |
| | | | 9 | (34.6%) | | | | |

```
가
4.
      В
                                         가
5.
                HBeAg
                                  17
                                         ΙgΑ
                                                     4
  (23.5%),
                          8 (47.1%)
                                     가
         5 (29.4%)
6.
   (hepatitis activity index)가 IgA
                                             가
  (p=0.011, p=0.039).
7.
                                                  ΙgΑ
                                            가
  (p=0.011, p=0.003).
       C3
                                               C4
8.
                  24
9.
                                         IgG
                                               C3가
            ΙgΑ
                       ΙgΑ
                            C3가
                 В
                                        가
                                                 가
                                                      가
                                         HBeAg
   , C3가
IgG C3
HBeAg, IgG
             C3
               В
```

В

< >

HBsAg ,

5 - 10% 90 5%

1. 0.2 - 1% , 0.2% HBV가 ².

B (HBV) HBV 가

HBsAg, HBeAg HBcAg ⁴. 가

- -

. HBV (membranous

glomerulonephritis), (membranoproliferative

II.

1.

1985 2000 6

HBsAg
, , , Henoch - Schönlein ,

, 26

2.

가.

Table 1 ,

.

Table 1. New histopathologic classification of chronic hepatitis

| Grading of chronic hepatitis | | | | | | |
|------------------------------|--|--|-------|--|--|--|
| Lobular act | ivity | | score | | | |
| None | No ne | crosis | 0 | | | |
| Minimal | | oidal lymphocytosis For less necrosis per 10 x objective field | 1 | | | |
| Mild | 2 - 5 n | ecrosis per 10 x objective field | 2 | | | |
| Moderate | 6 - 10 | necrosis per 10 x objective field | 3 | | | |
| Severe | or con | More than 10 necrosis per 10 x objective field, or confluent necrosis(zone 3) | | | | |
| Porto - Perip | oortal ac | ctivity | score | | | |
| None | <mi< td=""><td>ld portal inflammation</td><td>0</td></mi<> | ld portal inflammation | 0 | | | |
| Minimal | | > mild portal inflammation | | | | |
| Mild | | +/- focal piecemeal necrosis in a few portal tract | | | | |
| IVIIIU | | PMN [†] , focal in some or most portal tracts, or PMN < 50% in a few portal tracts | | | | |
| Moderate | | N, around < 50% in most portal tracts, or | 3 | | | |
| | | N, around > 50% in a few or some portal tracts | 6 | | | |
| Severe | | N, around < 50% in most portal tracts / | 4 | | | |
| Staging of c | | tal surfaces, or bridging necrosis | score | | | |
| No fibrosis | | Normal connective tissue | 0 | | | |
| Portal fibros | sis | Fibrous portal expansion | 1 | | | |
| Periportal fi | brosis | Periportal fibrosis with short septa extending Into lobules or rare porto - portal septa | 2 | | | |
| Septal fibrosis | | (intact architecture) Fibrous septa reaching adjacent portal tracts a terminal hepatic venule (architectural distortio but no obvious cirrhosis) | | | | |
| Cirrhosis | | Diffuse nodular formation | 4 | | | |

^{*} with or without

[†] piecemeal necrosis

IgA (minimal change nephrotic syndrome), (membranous glomerulonephritis) (membranoproliferative glomerulonephritis)

3.

B ,

4.

SPSS(Window release 9.0) Package 95%
71

Mann - Whitney U -

·

1.

가. B 1985 2000 6

HBsAg 26 . , HBV IgA 7


 27%,
 1 3.8%
 ,

 9 34.6%
 가 가 .

•

8 56 31.0±12.3 가 21 , 5 4.2:1 . , 1 가 34 , 25.9±11.3 가 10 30 39.1±9.0

가 30-40 가 , IgA 26.9±13.9 20 (Figure 1).



- * IgA Nephropathy
- † Membranous glomerulonephritis
- ‡ Membranoproliferative glomerulonephritis

Figure 1. Age distribution

Table 2 가 26 3.5g 가 14 44.4% . 14 IgA 4 1 (7.1%), (28.6%), 5 (35.7%),4 (28.6%) 26 26 16 AST ALT가 가 IgG, IgA, IgM 23 IgG 9 971.6 ± 539.7 mg/dl(800 - 1600 mg/dl) . IgA $299.8 \pm 213.0 \text{ mg/dl}$ 가 4 70 - 400 7 가 206.3 ± 140.5 mg/dl) , IgM

```
mg/dl( 40 - 250 mg/dl) .
 C3, C4 24
                              C3
                                       66.9 \pm 20.7
mg/dl( 90 - 180 mg/dl)
                                        , C4
 25.7 \pm 10.7 \text{ mg/dl}   10 - 40 \text{ mg/dl}
ASO titer 17
                                   , RF 12
           2 가 . ANA 17
            , anti - dsDNA 14
LE cell 9
              17 65.4% 17 IgA
HBeAg
                                              4
(23.5%),
                     8 (47.1%)
    5 (29.4%)
                            가
```

Table 2. Laboratory findings in patients with HBV-associated nephropathy at the time of biopsy

| | IgA* | MCNS† | MGN [‡] | MPGN § | Total |
|----------------------|-------------|-----------|------------------|------------|-------------|
| Number of cases | 7 | 1 | 9 | 9 | 26 |
| Mean Age(Years) | 27 ± 14 | 34 | 26 ± 11 | 39 ± 9 | 31 ± 12 |
| Range(Age) | 14-56 | 34 | 8-40 | 24-51 | 8-56 |
| Sex(Male:Female) | 4:3 | 1:0 | 8:1 | 8:1 | 21:5 |
| Urine | | | | | |
| Proteinuria>3.5g/day | 4/7 | 1/1 | 5/7 | 4/7 | 14/22 |
| Hematuria | 7/7 | 1/1 | 9/9 | 9/9 | 26/26 |
| Serum | | | | | |
| Increased AST/ALT | | | | | |
| (> 34 IU/L) | 3/7 | 1/1 | 7/9 | 5/9 | 16/26 |
| Decreased IgG | | | | | |
| (< 800 mg/dl) | 3/6 | 1/1 | 2/9 | 3/7 | 9/23 |
| Increased IgA | | | | | |
| (>400 mg/dl) | 2/6 | 0/1 | 0/9 | 2/7 | 4/23 |
| Increased IgM | | | | | |
| (> 250 mg/dl) | 2/6 | 0/1 | 2/9 | 3/7 | 7/23 |
| Decreased C3 | | | | | |
| (< 90 mg/dl) | 6/6 | 1/1 | 9/9 | 8/8 | 24/24 |
| Decreased C4 | | | | | |
| (< 10 mg/dl) | 0/6 | 0/1 | 0/9 | 0/8 | 0/24 |
| HBsAg | 7/7 | 1/1 | 9/9 | 9/9 | 26/26 |
| HBeAg | 4/7 | 0/1 | 8/9 | 5/9 | 17/26 |
| Anti-HBs | 0/7 | 0/1 | 0/9 | 0/9 | 0/26 |
| Anti-Hbe | 3/7 | 1/1 | 0/9 | 3/9 | 7/26 |
| Anti-HBc | 7/7 | 1/1 | 9/9 | 9/9 | 26/26 |
| HBV-DNA | 1/1 | Not check | 4/4 | Not check | 5/5 |

^{*} IgA Nephropathy

[†] Minimal change nephrotic syndrome

[‡] Membranous glomerulonephritis

[§] Membranoproliferative glomerulonephritis

Table 3

. $\mbox{IgG7} \ \ 13 \ \ , \mbox{IgA 16} \ \ , \mbox{IgM 12} \ \ , \mbox{C3}$ 15 \ , C4 10 \ , C1 7 \ , fibrinogen \ 10

ΙgΑ

IgA IgA C37

IgG C3가 IgA C3가

Table 3. Immunofluorescent findings in patients with HBV-associated nephropathy

| | No. of | Site of | | | | | | | Fibrin |
|-------------|--------|------------|-----|-----|-----|-----|-----|-----|--------|
| Nephropathy | cases | deposition | IgG | IgA | IgM | C3 | C4 | C1 | ogen |
| IgA | 7 | GCW^* | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | Mes † | 0 | 7 | 4 | 6 | 3 | 1 | 3 |
| | | GCW+Mes | 0/1 | 0/7 | 0/4 | 1/6 | 0/3 | 0/1 | 0/3 |
| MCNS | 1 | Mes | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| MGN | 9 | GCW | 9 | 4 | 4 | 3 | 3 | 2 | 3 |
| | | Mes | 1 | 0 | 2 | 1 | 1 | 1 | 2 |
| | | GCW+Mes | 1/9 | 0/4 | 2/4 | 0/4 | 1/3 | 0/3 | 2/5 |
| MPGN | 9 | GCW | 2 | 3 | 3 | 3 | 4 | 2 | 1 |
| | | Mes | 1 | 2 | 2 | 3 | 1 | 1 | 1 |
| | | GCW+Mes | 0/3 | 1/4 | 1/4 | 1/5 | 1/4 | 0/3 | 0/2 |
| Total | 26 | | 13 | 16 | 12 | 15 | 10 | 7 | 10 |

^{*} Glomerular capillary wall

[†] Mesangium

3. B

Table 4. Histopathologic characteristics of nephropathy according to new histopathologic classification of chronic B-viral hepatitis

| Liver patho | ology | | Renal pathology | | | | | |
|----------------|-------|-----|-----------------|-----|------|-------|--|--|
| Classification | Score | IgA | MCNS | MGN | MPGN | Total | | |
| Hepatitis | 0 - 2 | 5 | 0 | 0 | 3 | 8 | | |
| activity index | 3 - 4 | 2 | 1 | 9 | 6 | 18 | | |
| Fibrosis score | 0 - 1 | 6 | 1 | 1 | 1 | 9 | | |
| | 2 - 4 | 1 | 0 | 8 | 8 | 17 | | |

4. B




Figure 2. Lobular activity score according to histopathologic classification of nephropathy




Figure 3. Porto-periportal activity score according to histopathologic classification of nephropathy




Figure 4. Hepatitis activity index according to histopathologic classification of nephropathy

가 ΙgΑ , 1.0 ± 0.6 , 2.6 ± 1.2 , 2.9 ± 1.2 가 ΙgΑ 가 (p=0.011,p = 0.003) (Figure 5). p = 0.003p = 0.011p = 0.6124 00 0000 Fibrosis score 000 3 2.6 ± 1.2 000 000 2 0 1 1.0 ± 0.6 0 IgA MGN **MPGN** Nephropathy

Figure 5. Fibrosis score according to histopathologic classification of nephropathy

| В | | | | | | , | , | |
|-----------|--------------------|--------|-----------------------|-----|-----|-------|-------|--------|
| | . 5 | | | 33 | | В | | |
| 15 | | 가 | | 12 | | | , 2 | 가 |
| | 4 | | | | | | . 10 | 39 |
| В | | | 33 | | 가 | | , 20 | 가 |
| | | | | | | 26 | | |
| | 가 | 14 | (53.8%) | | 1 | 3.5g | | 가 |
| | | | | | | | | |
| | | | | | Н | ЗV | | |
| 1971 | Combes 11 | | | | | | | |
| (posttrar | nsfusion hepa | titis) | | 16 | | | | 53 |
| | Australia | | IgG | | | | | |
| | | | | | Н | BV | | |
| | | | | | | | | |
| | | | | | | 가 | | |
| | В | | | | | | 가 | |
| | | | | | | | | |
| 1979 | Morzycka | Slus | sarczyk ¹² | , | | | | 99 |
| | , HBsAg | | 55 | | 28 | | | 가 |
| | , 16 | | | НВ | sAg | 9 | | |
| | , HBsAg | | 44 | | | 4 | | |
| | HBsAg | | HE | 8V가 | | | | |
| | . , | | | | | | HB\ | / |
| | | | | | 가 | , | | |
| HBV | | | | | | | | Vos |
| 13 | 9.8% | | 20.3%, Na | agy | 14 | | 0.99% | , D |
| 13%. Ma | anna ¹⁵ | | 4.2% | | 31 | .7% . | | 16 |

```
17
        9.4%
                    25.3%,
                                             12.3%
                                                          17.1%
                        HBV
                                            HBV가
            가
 HBV
                 glomerulonephritis),
(membranous
(membranoproliferative glomerulonephritis),
   (mesangial proliferative glomerulonephritis)
                                                       가
 В
                                Lai
                                                          74
HBsAg
                                        25
                                               가
   IgA
                18,
                                          11
(minimal change nephrotic syndrome)
                                            . Bhimma
                                                           93
  HBsAg
                                         70
                         (focal segmental glomerulosclerosis)
  6,
                         5
                  20
                             87
                                    HBsAg
              29
                     가
                                                   18 , IgA
    16
                                           33
                                                  HBsAg
                                    가
                             13
       (minimal change nephrotic syndrome)
                                            9,
                                                         10
                                   5
                                         가
                                                             39
        6,
    HBsAg
                                          25
      9,
                                 3 ,
                                                               2
                             26
                9
                         가 가
                                 HBsAg
                가
                                   가
```

| | В | |
|----------------------------|---|----------|
| | В | |
| . Knieser ²¹ | 3 | 가 |
| , 20 4 , | , 5 1 가 | |
| , 1 В | , 1 | . 5 |
| , 1 가 | 5 | 4 , |
| | 가 26 | 가 |
| | 26 | |
| | 가 | |
| | 가 가 | |
| 1983 Amemiya ²² | , B | UD о А « |
| onit | HBsAg HBeAg | , HBeAg |
| endothelial area mesang | helial area , HBsAg _J ium | |
| HBeAg 10 | daltons , HBeAg - Ab | 100 |
| daltons | subepithelial area | |
| HBsAg - Ab | 200 daltons | |
| | subepithelial area | |
| subendothelial area | mesangium | , |
| HBeAg | , HBsAg | |
| | ²³ . HBeAg | |
| 17 65.4% | 8 (47.1%) | 가 |
| . HBeAg | | |

```
C3
                 24
                                      C4
                        В
                                      C3
가
    ΙgΑ
                В
. Lida <sup>24</sup> IgA 130 HBsAg
                                       4
(3.1\%)
      4 1 HBeAg
         4 HBsAg HBeAg
      HBsAg, HBeAg IgA
         . , Nagy <sup>14</sup> 가 HBsAg
                     HBsAg
0.99%
         ΙgΑ
                               16%
         HBsAg
                     31%
  , Lai <sup>25</sup> 122 IgA
                     17.2% HBsAg
                     HBsAg
               HBsAg HBcAg
   HBV가 IgA
        26
                          736 lgA
                          87 HBsAg
66 9%
       16 (17%)
                                IgA
   IgA
   26 7 (27%) IgA
                          HBV가
                           IgA C3가
                        26
                  В
                                      25.9
±11.3 ,
                     41.3 \pm 13.5
                        39.1 \pm 9.0
           32.5 \pm 14.5
           В
         HBeAg
                    , HBsAg
```

가 HBeAg C3가 IgG C3 HBeAg, IgG C3 가 .

가 .

| HI | BV | HBV | | | | | |
|----|---------------------|---------|-------------|------|----------|-------|--|
| | | | 가 | | | | |
| | HBV | | | | | , | |
| | | , | | | | В | |
| | | | | | | В | |
| | | | | . , | | | |
| | | | | Н | BV | | |
| | | | | | | | |
| | 1985 | 2000 | 6 | | | | |
| | | | | | | | |
| | HBs | HBsAg | | | | 26 | |
| | | | 04.0 | 40.0 | | 4.0.4 | |
| 1. | 26 | | 31.0± 가 | 12.3 | | 4.2:1 | |
| | 14 | | ∕ Γ | | | | |
| 2. | В | 26 | IgA | 7 | (27.0%), | | |
| ۷. | 1 (3.8 | | igA | | 34.6%) | | |
| | 1 (3.0 | 9 (34 | 4.6%) | | 34.070) | | |
| 3. | В | 0 (0- | 1.070) 가 | • | | | |
| 0. | J | | | | 가 | | |
| 4. | | | | | • | • | |
| | (hepatitis activity | v index |)가 IaA | | | | |
| | (- | , , | . 3 | | 가 | | |
| | (p=0.011, p=0.03 | 9). | | | | | |
| 5. | | , | | | | IgA | |
| | | | | | 가 | J | |
| | (n=0.011 n=0.00) | 3) | | | | | |

6. HBeAg 17 8 1gG C3가 (47.1%) 가 1gG T가 가 1gG C3가 가 가 1gG C3가 가 가 HBeAg T와 가 가 HBeAg HBeAg, 1gG C3

- 2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B: 2000 Summary of a workshop.Gastroenterology 2001;120:1828 53.
- 3. Gocke DJ. Extrahepatic manifestations of viral hepatitis. Am J Med Sci 1975;270(1):49 52.
- Eigenbrodt EH, Ware AJ. Renal involvement in hepatic disease. In: Tisher CC, Brenner BM Eds. Renal pathology with clinical and functional correlation. Philadelphia: JB Lippincott Co. 1989;525 - 8.
- 5. , B . 1992;26:215 28.
- 6. Wiggelinkhuizen J, Sinclair Smith C, Stannard LM, Smuts H. Hepatitis B virus associated membranous glomerulonephritis. Arch Dis Child 1983;58:488 96.
- 7. Kleinknecht C, Levy M, Peix A, Broyer M, Courtecuisse V. Membranous glomerulonephritis and hepatitis B surface antigen in children. J Pediatr 1979;95:946 52.
- 8. Brzosko W, Krawczynski K, Nazarewicz T, Morzycka M, Nowolslawski A. Glomerulonephritis associated with hepatitis B surface antigen immune complexes in children. Lancet 1974;2:477 82.
- 10. B . 1993;20(2):363 372.
- 11. Combes B, Stastny P, Shorey J, Eigenbrodt EH, Barrera A, Hull AR,

- et al.. Glomerulonephritis with deposition of Australia antigen antibody complexes is glomerular basement membrane. Lancet 1971;11:234 - 7.
- 12. Morzycka M, Slusarczyk J. Kidney glomerular pathology in various forms of acute and chronic hepatitis. Arch Pathol 1979;103:38 41.
- 13. Vos GH, Grobbelaar BG, Milner LV. A Possible relationship between persistent hepatitis - B antigenemia and renal disease in Southern African Bantu. S. Afr. Med 1973;12:109 - 14.
- 14. Nagy J, Bajtai G, Brasch H, Sule T, Ambrus M, Deak G, Hamori A. The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. Clin Nephrol 1979;12:109 - 13.
- Manna A LA, Polito C, Gado RD, Olivieri AN, Toro RD. Hepatitis B surface antigenemia and glomerulopathies in children. Acta Paediatr Scan 1985;74:122 - 5.
- 17. , , , B (HBsAg) Anti - HBs . 1982;25:750 - 6.
- Lai KN, Lai FM M, Chan KW, Chow CB, Tong KL, Valance Owen
 J. The clinicopathologic features of hepatitis B virus associated glomerulonephritis. Q J Med 1987;63:323 - 33.
- Bhimma R, Coovadia HM, Adhikari M. Hepatitis B virus associated nephropathy in black South African children. Pediatr Nephrol 1998;12:479 - 84.
- 20. Lee HS, Choi Y, Yu SH, Koh HI, Kim MJ, Ko KW. A renal biopsy study of hepatitis B virus-associated nephropathy in Korea. Kidney Int 1988;34:537 43.
- 21. Knieser MR, Jenis EH, Lowenthal DT, Bancroft WH, Burns W, Shalhonb R. Pathogenesis of renal disease associated with viral hepatitis. Arch Pathol 1974;97:193 200.

- 22. Amemiya S, Ito H, Kato H, Sakaguchi H, Hasegawa O, Hajikano H. A case of membranous proliferative glomerulonephritis type III(Burkholder) with the deposition of both HBeAg and HBsAg. Int J Pediatr Nephrol 1983;4:267 73.
- 23. , , , B 1 . 1986;3(1):325 - 32.
- 24. Lida H, Izumino K, Asaka M, Fujita M, Sasayama S. IgA nephropathy and hepatitis B virus. Nephron 1990;54:18 24.
- 25. Lai KN, Lai FM, Tam JS, Vallance Owen J. Strong association between IgA nephropathy and hepatitis B surface antigenemia in endemic areas. Clin Nephrol 1988;29(5):229 34.

Abstract

Histopathologic Correlation between Chronic B Viral Hepatitis and Nephropathy

Hyun Woong Lee

Brain Korea 21 project for Medical Science
The Graduate School, Yonsei University

(Directed by Professor Chae Yoon Chon)

Recent evidence indicates that B-viral hepatitis is sometimes associated with the production of extrahepatic tissue injury. However, the pathologic role of the HBV infection glomerulonephritis is not clear. There were some reports on clinical association between HBV infection and nephropathy. The relationship between HBV infection and nephropathy was reported with some differences according to the investigators and regions. Liver biopsies were not performed in most of the reports. However, in this study both liver and kidney biopsies were performed in all patients who were HBsAg positive and had proteinuria and hematuria. And, the histologic correlation was analyzed between chronic B viral hepatitis and nephropathy. Also, new histopathologic classification of chronic hepatitis was applied in the assessment of liver disease.

From January 1985 to June 2000, 26 patients who were HBsAg positive and had proteinuria and hematuria were examined.

1. Among 26 cases, the mean age was 31.0 \pm 12.3 years and the ratio of male to female was 4.2 to 1.

- 2. Light microscopy of kidney showed IgA nephropathy in 7 cases(27%), minimal change nephrotic syndrome(MCNS) in 1 case(3.8%), membranous glomerulonephritis(MGN) in 9 cases(34.6%), membranoproliferative glomerulonephritis (MPGN) in 9 cases(34.6%).
- Among cases with hepatitis B virus, in cases with higher hepatitis activity index and fibrosis score, the frequency of MGN and MPGN was higher.
- 4. The hepatitis activity index of cases with MGN was significantly higher than IgA nephropathy and MPGN(p=0.011, p=0.039).
- 5. The fibrosis score of cases with MGN and MPGN was significantly higher than IgA nephropathy (p=0.011, p=0.003).
- Seventeen cases were positive for HBeAg and nine cases were negative. The positivity of HBeAg was highest in cases with MGN.
- 7. Serum C3 level was low in all cases, but serum C4 level was within normal range.
- 8. Immunofluorescence studies showed granular deposition of IgG and C3 in the capillary loops in MGN.

In conclusion, the frequency of MGN and MPGN was higher when the liver disease was more severe, and it was suggested that HBeAg, IgG and C3 might contribute to the pathogenesis of MGN in HBsAg positive patients.

Key Words: Hepatitis B - virus, Nephropathy, Liver biopsy, Renal biopsy